Diasorin SpA DIA

Stock XMIL Rating as of Oct 1, 2026

€74.90 +0.90 (1.22%)

As of Oct 2, 2026, 3:35:14 PM Delayed Price Closed

Company Report

Diasorin's Sharper Specialty Focus Reinforces Our Narrow Moat Thesis

Max Jousma Sep 2, 2026

Diasorin is a niche player in the fragmented in-vitro diagnostics market, with a strong focus on specialty immunodiagnostics. The company provides testing equipment and reagents, creating recurring sales opportunities from its installed base. At its May 2026 investor day, Diasorin reaffirmed its positioning as a diagnostic specialist, with continued specialty menu expansion across all three business lines as the core driver of growth through 2030.

Read Analysis

Price vs Fair Value

View History

DIA is trading at a LOCK|FRTDc@Y premium.

Price

€74.00

Oct 1, 2026

Fair Value

May 27, 2026

Uncertainty

LOCK|#<&@

1-Star Price: LOCK|.^!W
5-Star Price: LOCK|.!
Economic Moat: LOCK|c&P%M
Capital Allocation: LOCK|D<^#@h

Bulls Say, Bears Say

Bulls

The innovative and flexible syndromic testing platform, Liaison Plex, will enable Diasorin to gain market share in the syndromic testing market.

Bears

Diasorin has been slow to enter the molecular point-of-care market, which could limit its ability to capture market share.

Trading Information

Previous Close Price: €74.00
Day Range: €72.80–75.06
52-Week Range: €52.34–80.38
Bid/Ask: €73.20 / €75.10
Shares Outstanding: 49.44M
Market Cap: €3.70B
Volume/Avg: 212,338 / 207,285

Key Statistics

Price/Earnings (Normalized): 25.76
Price/Sales: 3.54
Dividend Yield (Trailing): 1.76%
Dividend Yield (Forward): 1.76%
Dividend Payment Schedule: May
Total Yield: 10.77%

Company Profile

Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.

Sector: Healthcare
Industry: Diagnostics & Research
Stock Style Box: Mid Core
Total Number of Employees: 3,260
Website: https://www.diasoringroup.com

Competitors

Valuation

Metric	DIA	BIO	BIM
Price/Earnings (Normalized)	25.76	38.32	14.66
Price/Book Value	2.57	1.33	2.14
Price/Sales	3.54	3.70	2.30
Price/Cash Flow	17.18	25.79	10.41

Price/Earnings

DIA

BIO

BIM

Financial Strength

Metric	DIA	BIO	BIM
Quick Ratio	0.81	2.14	1.44
Current Ratio	1.79	3.14	2.30
Interest Coverage	7.37	6.38	38.68

Quick Ratio

DIA

BIO

BIM

Profitability

Metric	DIA	BIO	BIM
Return on Assets (Normalized)	7.09%	2.47%	9.12%
Return on Equity (Normalized)	13.48%	3.53%	12.43%
Return on Invested Capital (Normalized)	9.39%	2.66%	11.31%

Return on Assets

DIA

BIO

BIM

Diagnostics & Research Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Thermo Fisher Scientific Inc TMO	LOCK\|JC^>?@g	LOCK\|z@	$242B
Danaher Corp DHR	LOCK\|$G!kj#$	LOCK\|>>N	$150B
Agilent Technologies Inc A	LOCK\|p>gRr^GW	LOCK\|@q	$47B
IQVIA Holdings Inc IQV	LOCK\|%Q?&^<	LOCK\|&PNvf	$43B
Waters Corp WAT	LOCK\|l>t%SK	LOCK\|M>	$42B
Illumina Inc ILMN	LOCK\|#?Kpd><	LOCK\|VY^#L	$41B
IDEXX Laboratories Inc IDXX	LOCK\|$R<TvQT	LOCK\|s!n	$41B
Mettler-Toledo International Inc MTD	LOCK\|VJD&C!P%	LOCK\|t!ng	$30B
Quest Diagnostics Inc DGX	LOCK\|#@<^T$>	LOCK\|%S#!&	$26B
Labcorp Holdings Inc LH	LOCK\|msC?^tS	LOCK\|Qm!$j	$25B